Home
Storia in 2 fonti
Entrada shares dive as Duchenne results disappoint
While the company claimed a victory, analysts said data from a Phase 1/2 study fell short of expectations. Entrada shares subsequently tumbled more than 50%.
- ·
biopharmadive.com
Entrada shares dive as Duchenne results disappoint
While the company claimed a victory, analysts said data from a Phase 1/2 study fell short of expectations. Entrada shares subsequently tumbled more than 50%.
- ·
statnews.com
Next-gen Duchenne drug from Entrada disappoints
A next-gen Duchenne therapy from Entrada Therapeutics fell short in an early study, as a number of companies race to make improved drugs.